

Cancer Chemotherapy and Pharmacology

Volume 24 1989

Edited by

A. H. CALVERT, S. K. CARTER, M. J. EGORIN

Editorial Board

P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
R. L. Comis Philadelphia
T. Connors Carshalton
R. C. Coombes Sutton
M. d'Incalci Milan
C. Dittrich Vienna
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Victoria
S. Garattini Milano

A. Gouyette Villejuif
H. H. Hansen Copenhagen
A. Jeney Budapest
R. B. Livingston Seattle
J. S. Macdonald Lexington
T. J. McElwain Sutton
J. G. McVie London
F. M. Muggia Los Angeles
D. Newell Sutton
M. Ogawa Tokyo
G. Powis Rochester
M. Rozencweig Brussels

C. G. Schmidt Essen
H. J. Senn St. Gallen
C. Sessa Bellinzona
J. F. Smyth Edinburgh
S. Tsukagoshi Tokyo
T. Tsuruo Tokyo
F. A. Valeriote Detroit
L. M. van Putten Rijswijk
P. M. Wilkinson Manchester
P. Workman Cambridge
G. Wu Huan-Hsin Beijing



Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Founding editor: G. Mathé.

Editors: S. K. Carter, T. J. McElwain. As of volume 23 (1989): S. K. Carter, A. H. Calvert. As of volume 24 (1989): A. H. Calvert, S. K. Carter, M. J. Egorin.

Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1989

Contents of volume 24

No. 1 (pp 1-72) published 19 May, 1989
No. 2 (pp 73-140) published 2 June, 1989
No. 3 (pp 141-202) published 20 June, 1989
No. 4 (pp 203-268) published 17 July, 1989
No. 5 (pp 269-340) published 3 August, 1989
No. 6 (pp 341-402) published 18 September, 1989

This volume contains two supplements:

Supplement 1: 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Kornhuber B, Voûte PA (eds) Ifosfamide in the treatment of pediatric malignancies, S1-S52

Supplement 2: Proceedings of the Symposium "The cell membrane and cell signals as targets in cancer chemotherapy" (AACR, BACR, EORTC (PAM), Cambridge, U.K., September 1989, pp S53-S90 (Abstracts)

Abbruzzese JL → Ajani JA
Abdel-Hadi S → Gad-El-Mawla N
Achterrath W → Wander H-E
Adams L → Cassidy J
Addo M → Gad-El-Mawla N
Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanodia MD: Phase II study of Adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma 41
Angueira N → Schwartzman E
Aoki K → Kobayashi H
Arfeen S → Stark AN
Arnon R → Schechter B
Ash CM → Souhami RL
Auehakeekiat V → Cheirsilpa A
Avramis VI, Powell WC, Mecum RA: Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCK(-) 155
Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS: Pharmacodynamic and DNA methylation studies of high-dose 1-β-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia 203
Ayela P → Montagne N
Baba T → Kobayashi H
Baker LH → Chabot GG
Ballerini P, Franchi A, Fuschetti P, Piccioni D, Bonmassar E: Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide 359
Balli M → Demichelis R
Ballmer PE, Reinhart WH: Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum? 109
Baurain R → Ninane J
Bayssas M → Cassidy J
Begg EJ → Robinson BA
Behar C → Deméocq F
Benfenati E, Farina P, Colombo T, De Bellis G, Capodiferro MV, D'Incalci M: Metabolism and pharmacokinetics of

p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice 354
Benz-Lemoine E → Deméocq F
Beránek J → Novotný L
Bergerat JP → Herbrecht R
Bibby MC, Philips RM, Double JA: Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512) 87
Bielack SS, Erttmann R, Loeffl G, Purfürst C, Delling G, Winkler K, Landbeck G, Cooperative Osteosarcoma Study Group COSS: Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma 376
Bishop JF, Raghavan D, Oliver IN, Reece P, Morris R, Friedlander ML: A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion 246
Bissery M-C → Chabot GG
Bissery M-C → Chabot GG
Bleehen NM → Walton MI
Boder GG → Cassidy J
Boilletot A → Deméocq F
Boman BM → Ajani JA
Bonciarelli G → Demichelis R
Bonmassar E → Ballerini P
Bracco J → Montagne N
Brodfehrer JI, Wilke TJ, Kinder DH, Powis G: Preclinical pharmacologic studies of the new antitumor agent carmustazole (NSC-602668) in the mouse and beagle dog 277
Brunat-Mentigny M → Otten J
Brunat-Mentigny M → Deméocq F
Burde B, Haim N, Gez E, Poliak A: Acute myeloblastic leukemia following treatment with mitomycin C: a case report 71
Butler K → Marshall ME
Calaminus G → Göbel U
Caldani C → Montagne N
Cantrell J → Marshall ME
Cantwell BMJ → Carmichael J
Cao S, Zhen Y: Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B 181
Capodiferro MV → Benfenati E
Carey PJ → Stark AN
Carmichael J, Cantwell BMJ, Edwards CM, Zussman BD, Thompson S, Rapoport WG, Harris AL: A pharmacokinetic study of granisetron (BRL 43694 A), a selective 5-HT₃ receptor antagonist: correlation with anti-emetic response 45
Cassidy J, Lewis C, Adams L, Setanoians A, Bayssas M, Boder GG, Rankin EM, Kaye SB: Phase I clinical and pharmacokinetic study of LY 195448 233
Cassuto E → Montagne N
Catalano R → Hudes GR
Chabot GG, Bissery M-C, Corbett TH, Rutkowski K, Baker LH: Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice 15
Chabot GG, Bissery M-C, Gouyette A: Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro 273
Challoner T → Green JA
Chang S-P → Hu OY-P
Cheirsilpa A, Leelasethakul S, Auethaveekiat V, Maeolekulpriroj S, Kangsumrit N, Thanakaravit P, Phanthumjida P: High-dose mitomycin C: activity in hepatocellular carcinoma 50
Chen K-Y → Hu OY-P
Chetiyawardana SD, Cullen MH, Joshi RC, Woodroffe CM: Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer 102
Clarke J → Coleman R
Clark GM → Lathan B
Clausen HV → Sørensen PG
Coe MA → Green JA
Coleman R, Clarke J, Gore M, Wiltshaw E, Slevin M, Harper P: A phase II study of mitozantrone in advanced carcinoma of the ovary 200
Coleman RE → Gallagher CJ
Coley HM, Twentyman RP, Workman P: Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A 284
Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP: Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group study 128
Colls BM → Robinson BA
Colombo T → Benfenati E
Comis RL → Hudes GR
Contesso G → Deméocq F
Coombes RC → Hickish T
Cooperative Osteosarcoma Study Group COSS → Bielack SS
Corbett TH → Chabot GG
Correa G → Ninane J
Craft AW → Davies SM
Cullen MH → Chetiyawardana SD
Cummings J, Smyth JF: Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours 269
Cunningham D → Hickish T

9

Dahl GV → Mirro J Jr
 David JC → Zittoun J
 Davies SM, Pearson ADJ, Craft AW: Toxicity of high-dose ifosfamide in children S 8
 Davy M → Reece PA
 Deacon J → Walling JM
 De Bellis G → Benfenati E
 De Bock V → Van Belle SJP
 DeGregorio MW → Gandara DR
 Dehou M-F → Van Belle SJP
 DeLap RJ → Hudes GR
 Della Valentina M → Figoli F
 Delling G → Bielack SS
 Demaile MC → Deméocq F
 Demard F → Milano F
 Deméocq F, Oberlin O, Benz-Lemoine E, Boilletot A, Gentet JC, Zucker JM, Behar C, Poutard P, Olive D, Brunat-Mentigny M, Demaile MC, Platte C, Contesso G, Lemerle J: Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP) S 45
 Demicheli R, Jirillo A, Bonciarelli G, Lonardi F, Pradella M, Balli M: Factors causing dose variability in drug administration 363
 Denham A → Gandara DR
 Devenport K → Slevin ML
 Dickinson R, Presgrave P, Levi J, Milliken S, Woods R: Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma 67
 Dikdan G → Hu JJ
 Dimaira MJ → Hu JJ
 D'Incalci M → Benfenati E
 Domae N → Ueda T
 Donehower RC → Grochow LB
 Dopfer R → Henze G
 Double JA → Bibby MC
 Douglass EC → Pratt CB
 Duclos B → Herbrecht R
 Dufour P → Herbrecht R
 Dutou L → Otten J

Earl HM → Souhami RL
 Ebert J → Lenk H
 Edwards CM → Carmichael J
 Efremidis AP → Kandylis K
 Eibl H → Vehmeyer K
 Elslager EE → Lathan B
 El-Taner O → Gad-El-Mawla N
 Errante D → Figoli F
 Errington RD → Green JA
 Erttmann R → Bielack SS
 Etcubanas EL → Pratt CB
 Ettinger DS → Grochow LB
 Exner U → Jürgens H

Faintuch JS → Ajani JA
 Falkson G, Zyl AJ van: A phase I study of a new 5HT₃-receptor antagonist granisetron, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting 193
 Farghali H → Novotny L
 Farina P → Benfenati E
 Fengler R → Henze G

Ferster A → Ninane J
 Figoli F, Veronesi A, Trovo MG, Errante D, Della Valentina M, Zagonel V, Talamini R, Magri MD, Monfardini S: Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer 381
 Flamant F → Otten J
 Floris C → Sulis E
 Ford CHJ, Richardson VJ, Tsaltas G: Comparison of tetrazolium colorimetric and [³H]-uridine assays for in vitro chemosensitivity testing 295
 Franchi A → Ballerini P
 Francois E → Milano F
 Freeman S → Reece PA
 Freney M → Milano F
 Friedlander ML → Bishop JF
 Fukuroda T → Yoshinari T
 Fuschietti P → Ballerini P

Gad-El-Mawla N, Hussein MH, Abdel-Hadi S, El-Taner O, Addo M, Magrath I: Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen S 20
 Gál F → Institórius E
 Gallagher CJ, Wilshaw E, Coleman RE, Harper PG: A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer 54
 Gandara DR, Perez EA, Denham A, Wiebe VJ, DeGregorio MW: Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens 135
 Garcia JJ → Herbrecht R
 Geddes DM → Souhami RL
 Gentet JC → Deméocq F
 Gez E → Burde B
 Giglio W → Pogach LM
 Göbel U → Henze G
 Göbel U, Calaminus G, Haas RJ, Jürgens H, Niethammer D, Ritter J, Spaar HJ, Harms D: Combination chemotherapy in malignant non-seminomatous germ-cell tumors: results of a cooperative study of the German Society of Pediatric Oncology (MAKEI 83) S 34
 Göbel U → Jürgens H
 Goldstone AH → Souhami RL
 Gore M → Coleman R
 Goren MP → Pratt CB
 Gorycki P → Latham MD
 Goudeau → Ajani JA
 Gouyette A → Chabot GG
 Gouyette A → Vassal G
 Graf N → Henze G
 Green AA → Pratt CB
 Green JA, Watkin SW, Hammond P, Griggs J, Challoner T: The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting 137
 Green JA, Errington RD, Nash JRG, Coe MA, Warenius HM: Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma 326

Grier HE → Mirro J Jr
 Griffin BR → Collins C
 Griggs J → Green JA
 Grillo-Lopez AJ → Hudes GR
 Grochow LB, Noe DA, Ettinger DS, Donehower RC: A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics 314
 Groot G de → Storm G

Haas RJ → Göbel U
 Haim N → Burde B
 Hajichristou HT → Souhami RL
 Hameleke K → Sebolt J
 Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D₂ and 5-hydroxy-tryptamine₂ receptors 307
 Hammond P → Green JA
 Hansen HH → Sørensen PG
 Harms D → Göbel U
 Harper P → Coleman R
 Harper PG → Gallagher CJ
 Harper PG → Souhami RL
 Harris AL → Carmichael J
 Hartmann O → Vassal G
 Hartmann R → Henze G
 Harvey VJ → Slevin ML
 Hasuda K → Kobayashi H
 Havlick M → Sebolt J
 Haydock A → Hickish T
 Hayes FA → Pratt CB
 Heimer R, Sartorelli AC: RNA polymerase II transcripts as targets for 5-fluorouridine cytotoxicity: antagonism of 5-fluorouridine actions by α-amanitin 80
 Henze G, Fengler R, Hartmann R, Dopfer R, Göbel U, Graf N, Jürgens H, Niethammer D, Ritter J, Schellong G, Siebert W: Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia S 16
 Herbrecht R, Garcia JJ, Bergerat JP, Dufour P, Duclos B, Oberling F: VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen 338
 Hickish T, Cunningham D, Haydock A, Coombes RC: Experience with intermediate-dose (110–120 mg/m²) epirubicin 61
 Higano CS → Collins C
 Hillen FC → Storm G
 Hoesel QGCM van → Storm G
 Hoff DD von → Lathan B
 Holcenberg JS → Avramis VI
 Holliday S → Walling JM
 Hopewell JW → Yeung TK
 Horowitz ME → Pratt CB
 Huang HFS → Pogach LM
 Hudes GR, LaCreta F, DeLap RJ, Grillo-Lopez AJ, Catalano R, Comis RL: Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil 117
 Hu JJ, Dimaira MJ, Zirvi KA, Dikdan G, Lea MA: Influence of pH on the modification of thiols by carbamoylating agents

and effects on glutathione levels in normal and neoplastic cells 95

Hu OY-P, Chang S-P, Jame J-M, Chen K-Y: Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients 332

Hussein MH → Gad-El-Mawla N

Inaba M → Tashiro T

Institóris E, Szikla K, Ötvös L, Gál F: Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol 311

Iwasawa Y → Yoshinari T

Jackson G → Stark AN

Jackson R → Sebolt J

Jame J-M → Hu OY-P

Jankú I → Novotný L

Jeffery GM → Robinson BA

Jirillo A → Demicheli R

Joel SP → Slevin ML

Joshi RC → Chetiyawardana SD

Jürgens H → Henze G

Jürgens H → Göbel U

Jürgens H, Exner U, Kühl J, Ritter J, Treuner J, Weinel P, Winkler K, Göbel U: High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma 840

Kagawa D → Ueda T

Kalwinsky DK → Mirro J Jr

Kandylis K, Vassilomanolakis M, Tsouassis S, Efremidis AP: Ifosfamide cardiotoxicity in humans 395

Kangsumrit N → Cheirsilpa A

Kanojia MD → Ajani JA

Kaye SB → Cassidy J

Keim M → Treuner J

Keppen MD → Collins C

Keyes SR → Rockwell S

Khokhar AR → Perez-Soler R

Kim DJ → Vehmeyer K

Kinder DH → Brodfuehrer JI

King CK → Latham MD

Klapötke T → Köpf-Maier P

Kobayashi H, Hasuda K, Aoki K, Kuroiwa T, Taniguchi S, Baba T: "Two-route chemotherapy" using *cis*-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, combined with angiotsensin II is effective against peritoneally disseminated cancer in rats 141

Kobayashi T → Tashiro T

Köpf H → Köpf-Maier P

Köpf-Maier P, Neuse E, Klapötke T, Köpf H: Ionic titanocene complexes: a new type of antitumor agent 23

Kop W → Storm G

Kornhuber B: Preface S I

Koscielniak E → Treuner J

Kraker J de → Ninane J

Kraker J de, Voûte PA: Experience with ifosfamide in paediatric tumours 828

Kühl J → Jürgens H

Kuroiwa T → Kobayashi H

LaCreta F → Hudes GR

Landbeck G → Bielack SS

Latham MD, King CK, Gorycki P, Macdonald TL, Ross WE: Inhibition of topoisomerases by fredericamycin A 167

Lathan B, Hoff DD Von, Clark GM, Elslager EE: Evaluation of an amsacrine analog in a human tumor cloning system 230

Lautersztain J → Perez-Soler R

Lea MA → Hu JJ

Lee C → Mistry P

Leelasethakul S → Cheirsilpa A

Lee Y → Pogach LM

Lemerle J → Vassal G

Lemerle J → Deméocq F

Lenk H, Tanneberger St, Müller U, Ebert J, Shiga T: Phase II clinical trial of high-dose recombinant human tumor necrosis factor 391

Leopold W → Sebolt J

Levi J → Dickinson R

Levin B → Ajani JA

Lewis C → Cassidy J

Livingston RB → Collins C

Lonardi F → Demicheli R

Loof G → Bielack SS

Macdonald TL → Latham MD

Magrath I → Gad-El-Mawla N

Magri MD → Figoli F

Maniey D → Zittoun J

Maoleekulpairoj S → Cheirsilpa A

Marquet J → Zittoun J

Marshall ME, Butler K, Cantrell J, Wiseman C, Mendelsohn L: Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study 65

Mårtensson G, Sörenson S: A phase II study of vincristine in malignant mesothelioma - a negative report 133

Martin DS, Stolfi RL, Sawyer RC: Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylcytosine 9

Maruo K → Tashiro T

Mason C → Mirro J Jr

Massidda C → Sulis E

Maybaum J, Ting P, Rogers CE: Prediction of thioguanine-induced cytotoxicity by dualparameter flow cytometric analysis 291

McBrien DCH → Mistry P

Mecum RA → Avramis VI

Mecum RA → Avramis VI

Mendelsohn L → Marshall ME

Mestroni G → Sava G

Meyer D → Wander H-E

Meyer WH → Pratt CB

Milano G, Thyss A, Santini J, Frenay M, Francois E, Schneider M, Demard F: Salivary passage of 5-fluorouracil during continuous infusion 197

Milano G → Montagne N

Miles DW → Souhami RL

Miller TP → Collins C

Milliken S → Dickinson R

Mirro J Jr, Kalwinsky DK, Grier HE, Santana VM, Mason C, Murphy SB, Dahl GV: Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine 123

Mistry P, Lee C, McBrien DCH: Intracellular metabolites of cisplatin in the rat kidney 73

Miura K → Yoshinari T

Monfardini S → Figoli F

Montagne N, Milano G, Caldani C, Bracco J, Ayela P, Cassuto E, Thys A, Schneider M: Removal of methotrexate by hemodiafiltration 400

Morris R → Bishop JF

Morris R → Reece PA

Müller U → Lenk H

Murphy SB → Mirro J Jr

Nagel GA → Vehmeyer K

Nagel G-A → Wander H-E

Nakamura T → Ueda T

Nash JRG → Green JA

Naumoff M → Pogach LM

Nelson J → Sebolt J

Neuse E → Köpf-Maier P

Niethammer D → Henze G

Niethammer D → Göbel U

Ninane J, Baurain R, Kraker J de, Ferster A, Trout A, Cornu G: Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children 82

Noe DA → Grochow LB

Nomura T → Tashiro T

Novotný L, Farghali H, Jankú I, Beránek J: The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum 238

Nyce J → Avramis VI

Oberling F → Herbrecht R

Oberlin O → Deméocq F

Ohnishi Y → Tashiro T

Okura A → Yoshinari T

Olive D → Otten J

Olive D → Deméocq F

Olver IN → Bishop JF

Osborne RJ → Slevin ML

Otten J, Flamant F, Rodary C, Brunat-Mentigny M, Dutou L, Olive D, Quintana E, Voûte PA: Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy. (A SIOP study) 830

Ötvös L → Institóris E

Pacor S → Sava G

Paul C → Tidefelt U

Pearson ADJ → Davies SM

Pedersen H → Sørensen PG

Perez EA → Gandara DR

Perez-Soler R, Lautersztain J, Stephens LC, Wright K, Khokhar AR: Preclinical toxicity and pharmacology of liposome-entrapped *cis*-bis-neodecanoato-*trans*-R,R-1,2-diaminocyclohexane platinum (II) 1

Peroutka SJ → Hamik A

Phanthumjida P → Cheirsilpa A

Philips RM → Bibby MC

Piccioni D → Ballerini P

Pico JL → Vassal G
 Pinkerton CR, Pritchard J: A phase II study of ifosfamide in paediatric solid tumours S 13
 Platé C → Deméocq F
 Pogach LM, Lee Y, Giglio W, Naumoff M, Huang HFS: Zinc acetate pretreatment ameliorates cisplatin-induced Sertoli cell dysfunction in Sprague-Dawley rats 177
 Polliack A → Burde B
 Poutard P → Deméocq F
 Powell WC → Avramis VI
 Powis G → Brodfeuerer JI
 Pradella M → Demicheli R
 Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA: Ifosfamide in pediatric malignant solid tumors S 24
 Presgrave P → Dickinson R
 Pritchard J → Pinkerton CR
 Proctor SJ → Stark AN
 Purfürst C → Bielack SS
 Quintana E → Otten J
 Raghavan D → Bishop JF
 Ramu A, Yagen B, Ramu N: The cytotoxicity of T-2 toxin and related 12,13-epoxytrichothecenes to Adriamycin-sensitive and -resistant P388 leukemia cells 264
 Ramu N → Ramu A
 Rankin EM → Cassidy J
 Rapeport WG → Carmichael J
 Rauschning W → Wunder H-E
 Reece P → Bishop JF
 Reece PA, Stafford I, Davy M, Morris R, Freeman S: Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer 256
 Reinhart WH → Ballmer PE
 Reynolds CP → Tomayko MM
 Richardson VJ → Ford CHJ
 Ritter J → Henze G
 Ritter J → Göbel U
 Ritter J → Jürgens H
 Robinson BA, Begg EJ, Colls BM, Jeffery GM, Sharman JR: Circadian pharmacokinetics of methotrexate 397
 Rockwell S, Keyes SR, Sartorelli AC: Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo 349
 Rodary C → Otten J
 Rogers CE → Maybaum J
 Rosing MA → Schechter B
 Ross WE → Latham MD
 Rutkowski K → Chabot GG
 Sakurai Y → Tashiro T
 Santana VM → Mirro J Jr
 Santini J → Milano F
 Sartorelli AC → Heimer R
 Sartorelli AC → Rockwell S
 Sasada M → Ueda T
 Sava G, Zorzet S, Pacor S, Mestroni G, Zassinovich G: Effects of two pyridinal-alkyliminerhodium (I) complexes in mice bearing MCA mammary carcinoma 302
 Sawyer RC → Martin DS
 Schechter B, Rosing MA, Wilchek M, Arnon R: Blood levels and serum protein binding of *cis*-platinum (II) complexed to carboxymethyl-dextran 161
 Schellong G → Henze G
 Schneider M → Milano F
 Schneider M → Montagne N
 Schossig U → Sonka J
 Schwartzman E, Scopinaro M, Angueyra N: Phase II study of ifosfamide as a single drug for relapsed paediatric patients S 11
 Scopinaro M → Schwartzman E
 Sebold J, Havlick M, Hameleke K, Nelson J, Leopold W, Jackson R: Activity of the pyrazoloacridines against multidrug-resistant tumor cells 219
 Setanoians A → Cassidy J
 Sharman JR → Robinson BA
 Shiga T → Lenk H
 Siegert W → Henze G
 Simmonds RH → Yeung TK
 Slevin M → Coleman R
 Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation 329
 Smyth JF → Cummings J
 Sonka J, Schossig U, Vogt-Schaden M, Volm M: Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug 33
 Sorensen PG, Pedersen H, Clausen HV, Hansen HH: Tallysomycin S₁₀b - a phase I trial 113
 Sörenson S → Mårtensson G
 Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM, Goldstone AH, Spiro SG, Geddes DM, Tobias JS: Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer 321
 Spaar HJ → Göbel U
 Spiro SG → Souhami RL
 Stafford I → Reece PA
 Stark AN, Jackson G, Carey PJ, Arseen S, Proctor SJ: Severe renal toxicity due to intermediate-dose methotrexate 243
 Steele DA → Avramis VI
 Steerenberg PA → Storm G
 Stephens LC → Perez-Soler R
 Stolfi RL → Martin DS
 Storm G, Hoesel QGCM van, Groot G de, Kop W, Steerenberg PA, Hillen FC: A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat 341
 Stratford IJ → Walling JM
 Sugiyama M → Ueda T
 Sulis E, Floris C, Massidda C: Intralymphatic infusion of interferon in patients with lymph nodal metastases from melanoma of the lower limbs 393
 Sundman-Engberg B → Tidefelt U
 Suzuki K → Yoshinari T
 Szikla K → Institutóris E
 Takahashi IS → Yoshinari T
 Talamini R → Figoli F
 Taniguchi S → Kobayashi H
 Tanneberger St → Lenk H
 Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T: Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses 187
 Thanakaravit P → Cheirsilpa A
 Thompson EI → Pratt CB
 Thompson S → Carmichael J
 Thyss A → Milano F
 Thyss A → Montagne N
 Tidefelt U, Sundman-Engberg B, Paul C: Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epidoxorubicin in patients with acute leukemia 225
 Ting P → Maybaum J
 Tobias JS → Souhami RL
 Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice 148
 Tournade MF: A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor S 31
 Treuner J → Jürgens H
 Treuner J, Koscielniak E, Keim M: Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas S 48
 Trouet A → Ninane J
 Trovo MG → Figoli F
 Tsaltas G → Ford CHJ
 Tsouassis S → Kandylis K
 Twentyman PR → Coley HM
 Uchida M → Ueda T
 Uchino H → Ueda T
 Ueda T, Nakamura T, Kagawa D, Uchida M, Domae N, Sugiyama M, Ueda Y, Sasada M, Uchino H: Clinical pharmacology of N⁴-palmitoyl-1-β-D-arabinofuranosylcytosine in patients with hematologic malignancies 371
 Ueda Y → Ueda T
 Ueyama Y → Tashiro T
 Unger C → Vehmeyer K
 Van Belle SJP, Dehou M-F, De Bock V, Volckaert A: Nail toxicity due to the combination Adriamycin-mitoxantrone 69
 Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerie J: Pharmacokinetics of high-dose busulfan in children 386
 Vassilomanolakis M → Kandylis K
 Vehmeyer K, Kim DJ, Nagel GA, Eibl H, Unger C: Effect of ether lipids on mouse granulocyte-macrophage progenitor cells 58
 Veronesi A → Figoli F
 Vile GF, Winterbourn CC: Microsomal lipid peroxidation induced by Adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study 105

Vogt-Schaden M → Šonka J
 Volckaert A → Van Belle SJP
 Volm M → Šonka J
 Voûte PA → Kraker J de
 Voûte PA → Otten J
 Voûte PA: Closing remarks S 51

Wagner T: Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children – a comment S 7

Walling JM, Deacon J, Holliday S, Stratford IJ: High uptake of RSU 1069 and its analogues into melanotic melanomas 28

Walton MI, Bleehen NM, Workman P: Effects of elevated temperature on misondazole O-demethylation by mouse liver microsomes: kinetic and stability studies of a model mixed-function oxidase reaction 172

Wander H-E, Rauschning W, Meyer D, Achterrath W, Nagel G-A: Phase II study with etoposide in previously untreated advanced breast cancer 261

Warenius HM → Green JA
 Watkin SW → Green JA
 Weinel P → Jürgens H
 Whomsley R → Slevin ML
 Wiebe VJ → Gandara DR
 Wilchek M → Schechter B
 Wilimas JA → Pratt CB
 Wilke TJ → Brodfuehrer JI
 Wiltshaw E → Gallagher CJ
 Wiltshaw E → Coleman R
 Winkler K → Bielack SS
 Winkler K → Jürgens H
 Winterbourn CC → Vile GF
 Wiseman C → Marshall ME
 Woodroffe CM → Chetiyawardana SD
 Woods R → Dickinson R
 Workman P → Walton MI
 Workman P → Coley HM
 Wrigley PFM → Slevin ML
 Wright K → Perez-Soler R

Yagen B → Ramu A
 Yeung TK, Simmonds RH, Hopewell JW: The relative toxicity of intravenous and intraperitoneal doses of epirubicin 211

Yoshinari T, Iwasawa Y, Miura K, Takahashi IS, Fukuroda T, Suzuki K, Okura A: Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity 367

Zagonel V → Figoli F
 Zassinovich G → Sava G
 Zhen Y → Cao S
 Zirvi KA → Hu JJ
 Zittoun J, Marquet J, David JC, Manley D, Zittoun R: A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines 251

Zittoun R → Zittoun J
 Zorzet S → Sava G
 Zucker JM → Deméocq F
 Zussman BD → Carmichael J
 Zyl AJ van → Falkson G